Singapore: The Singapore Court Of Appeal Rules On Post Grant Amendments To Patents And Validity Of Second Medical Use Claims

Last Updated: 18 August 2017
Article by Arthur Yap

On 1 August 2017, the Singapore Court of Appeal in Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2017] SGCA 45 dismissed Warner-Lambert's application to amend its patent for the use of pregabalin for the treatment of pain (the "Patent").

Background

On 21 April 2015, Warner-Lambert commenced an action against Novartis in Singapore for infringement of its Patent. Novartis filed a defence and counterclaim seeking revocation of the Patent on the ground that the Patent was invalid as it claimed a monopoly over methods of treatment of the human or animal body, something impermissible under Singapore's patent law. Warner-Lambert thereafter applied for leave to amend the Patent to cure the invalidity in the Patent's granted claims.

It is useful to note that Singapore's patent system was a self-assessment system. Under this self-assessment system, the Intellectual Property Office of Singapore ("IPOS") did not conduct an independent search and examination to determine if the invention was patentable. Instead, the burden was on the applicant to self-certify the patent's compliance with the patentability requirements under the Patents Act. On 14 February 2014, the self-assessment system was replaced by a "positive-grant" system which remains in force today. Under the "positive-grant" system, IPOS makes a positive determination on whether the patent application complies with the patentability of the Patents Act.

Of importance to this judgment was the fact that Warner-Lambert's Patent was filed under the self-assessment system.

The Court's Exercise of Discretion to Allow Post-Grant Amendments

The decision is a timely reminder that the power to allow a post-grant amendment of patents pursuant to section 83 of the Patents Act, when parties are in the midst of court proceedings, is a discretionary one. The Court of Appeal stressed that even if the amendment does not disclose additional matter or extend the protection conferred by the patent, it retains the general discretion to refuse an amendment application.

Applying Smith Kline & French Laboratories Limited v Evans Medical Limited [1989] FSR 561, the Court of Appeal held that Warner-Lambert had unduly delayed in seeking the amendments for more than a decade. Notwithstanding the long delay indicating that it was an unreasonable one, the Court noted that Warner-Lambert had obtained an International Preliminary Examination Report from the European Patent Office acting as an International Preliminary Examining Authority under the Patent Cooperation Treaty which stated that "[c]laims directed to methods of treatment of the human or animal body by therapy might be found inadmissible in some patent systems" in February 1998. In December 1998, Warner-Lambert filed the Patent's corresponding European application with an accompanying amendment to the claims from method of treatment claims to Swiss-style claims, but did not do the same for the Patent in Singapore. In addition, Warner-Lambert had also amended some of its other Singapore patent applications pre-grant from method of treatment claims to Swiss-style claims in 2005, 2007, and 2008. Accordingly, the Court of Appeal, stating that the appropriate juncture to question whether the amending party has been guilty of an unreasonable delay is the time it was first made aware of the need to amend, found that Warner-Lambert had known or ought to have known that the Patent was problematic but had chosen not to take any steps to find out more or to amend the Patent.

Further, the Court of Appeal emphasized that a strict approach was adopted as the Patent had been granted under the self-assessment system. Patentees under the self-assessment system are under an obligation to make a considered decision before proceeding to obtain a grant of the Patent, and should not be given the liberty of taking a lackadaisical approach in ensuring compliance with the requirements of patentability. The Court of Appeal further opined that a lenient approach would only encourage dilatory conduct and wilful blindness on the part of the patentees.

In addition to the unreasonable delay in seeking the amendments to the Patent, the Court of Appeal also held that a patent granted under the self-assessment system which is obviously invalid in its totality, and where such invalidity is attributed solely to the patentee, such invalidity would be fatal to any amendment application. As the Patent is obviously invalid as it claims a method of treatment, it confers no protection whatsoever. Thus, the Court of Appeal thus held that Warner-Lambert's amendment application sought to validate that which is not valid from the beginning.

Validity of Swiss-style Claims and Subsequent Medical Use Claims

Recognising that the validity of Swiss-style claims has yet to be considered by the Singapore courts, the Court of Appeal, in obiter dicta, adopted a liberal interpretation of section 14(7) of the Patents Act, which mirrors section 2(6) of the UK Patents Act 1977, and opined that it recognises new uses of known substances as long as the new uses do not form part of the state of the art. In coming to its opinion, the Court of Appeal diverged from the English jurisprudence, and was of the view that the words "any such method" refer to a "method of treatment of the human or animal body by surgery or therapy or of diagnosis practised on the human or animal body" in the earlier half of the provision, and that in no way prevents section 14(7) from bearing the meaning that any use, first of subsequent, which is not part of the state of the art, is novel. If this wider interpretation is adopted, the Court of Appeal remarked that there would be no need to resort to Swiss-style claims, which involve, as observed by the High Court judge, a "fiction (implicit) behind the finding of novelty in the method of manufacture on the basis of a new therapeutic use".

The Court of Appeal also recognised that there are certain practical difficulties in recognising Swiss-style claims and enforcing them in infringement actions: the law is struggling to balance rewarding the patentee for elucidating a new use for the drug, whilst not excluding competing manufacturers from making and marketing the drug for its known purpose (as observed by Floyd LJ in Warner-Lambert Company LLC v Generics (UK) Ltd (trading as Mylan) and others [2016] EWCA Civ 1006). However, the Court stated that if their interpretation of section 14(7) is given the meaning discussed above, the novel and perhaps questionable use of Swiss-style claims to get around the perceived meaning of section 14(7) will no longer be necessary; a purpose-limited product claim in the form of "Compound X for use in the treatment of disease Y" would suffice.

Conclusion

The first key takeaway, namely the exercise of the Court's discretion to allow post-grant amendments and more specifically on the factor of undue delay, is a timely reminder for patentees in Singapore to make any such amendment where necessary expeditiously. This would be more pertinent where the patent in question was granted before 14 February 2014, under Singapore's then self-assessment regime.

Second, as regards Swiss-style claims and subsequent medical use claims, while the Court of Appeal did caveat that parties had not made full arguments on this issue, it is clear that the Court is prepared to adopt a wider interpretation of section 14(7) in order to allow subsequent medical use claims. However, whether or not the Court will validate Swiss-style claims remains uncertain given that the Court had opined that the use of Swiss-style claims is questionable and rest on a legal fiction. Nevertheless, it appears that subsequent medical use claims will be accepted and patentable in Singapore as a purpose-limited product claim.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions